Biohit Healthcare

What Biohit Healthcare does

Biohit Oyj (Biohit Healthcare) is a Finnish publicly-traded biotechnology company listed on the NASDAQ OMX Helsinki Small Cap exchange under ticker BIOBV, headquartered in Helsinki with wholly-owned subsidiaries in Italy and the UK. The company develops, manufactures, and markets diagnostic tests and analysis systems with a primary focus on gastrointestinal disease detection through proprietary biomarker panels, most notably GastroPanel — a blood-based panel of pepsinogen I, pepsinogen II, gastrin-17, and H. pylori antibodies used as a non-invasive 'serological biopsy' for atrophic gastritis and gastric cancer risk assessment.

The product portfolio spans four categories: (1) diagnostic tests including GastroPanel (quick test and Unified ELISA formats), laboratory ELISA tests (Active B12/HoloTC, Vitamin D, Calprotectin), and quick tests (ColonView FIT for colorectal cancer screening, Celiac, H. pylori, Lactose Intolerance); (2) the GP Reader NT laboratory instrument and GastroSoft software for test interpretation; (3) CE-marked Acetium consumer medical devices — capsules and lozenges based on slow-release L-cysteine technology that binds carcinogenic acetaldehyde in the stomach or saliva, respectively; and (4) a portfolio of monoclonal antibodies for research applications in cellular pathology, neurobiology, and oncology manufactured under ISO 13485.

Biohit monetizes primarily through one-time sales of diagnostic kits, instruments, and medical devices via a global distributor network, supplemented by direct sales to healthcare facilities and laboratories, direct-to-consumer e-commerce through Biohitshop for Acetium products, and B2B sales of research-grade monoclonal antibodies. The company serves three distinct customer segments: healthcare professionals (gastroenterologists, GPs, diagnostic labs), individual consumers (particularly those with hypochlorhydria or seeking smoking cessation support), and investors via dedicated NASDAQ OMX Helsinki investor relations.

Name

Biohit Healthcare

Legal name

Biohit Oyj

Website

https://biohithealthcare.com

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

11–50 employees

Short description

Biohit Oyj is a Finnish publicly-traded biotechnology company (BIOBV, NASDAQ OMX Helsinki Small Cap) that develops and markets diagnostic tests, laboratory instruments, CE-marked Acetium medical devices for acetaldehyde binding, and research-grade monoclonal antibodies, serving healthcare professionals, laboratories, and consumers globally through distributor and e-commerce channels.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), General Gastroenterology (HLAKAEAA), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• In vitro diagnostics
• Gastric disease diagnostics
• Monoclonal antibodies
• Medical device manufacturing
• Biotechnology research reagents

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Products: Biohit generates revenue through the sale of diagnostic test kits (GastroPanel, quick tests, ELISA tests), laboratory instruments (GP Reader NT), and monoclonal antibodies to healthcare facilities, laboratories, and research institutions.
2. Medical Devices: Sale of CE-marked Acetium medical device products (capsules and lozenges) to consumers and healthcare providers for stomach protection and smoking cessation.
3. Monoclonal Antibodies: Sale of monoclonal antibodies for research use (RUO) and as raw materials for the IVD industry. Products include antibodies to ECM components, spectrins, cytoskeletal proteins, neurotransmitters, gastric biomarkers, integrins, and other targets.
4. E-commerce Consumer Sales: Direct-to-consumer sales of Acetium products through Biohitshop online store.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels9 records

Core offering

Biohit develops, manufactures, and markets proprietary diagnostic tests and analysis systems — most notably the GastroPanel® biomarker panel — for non-invasive detection of atrophic gastritis and gastric cancer risk. The portfolio also includes CE-marked Acetium® medical devices (slow-release L-cysteine capsules and lozenges) that bind carcinogenic acetaldehyde, point-of-care quick tests (ColonView FIT, Celiac, H. pylori, Lactose Intolerance), ELISA laboratory tests, the GP Reader NT instrument, GastroSoft software, and a portfolio of monoclonal antibodies for research use.

Product overview

Biohit Healthcare is a Finnish biotechnology company offering a portfolio of diagnostic tests, medical devices, and research reagents. The core product line centers on GastroPanel®, a non-invasive diagnostic concept using serum biomarkers (pepsinogen I, pepsinogen II, gastrin-17, and H. pylori antibodies) available as quick test (NT), Unified ELISA, and GastroSoft software, complemented by the GP Reader NT instrument. The company also provides laboratory tests (Active B12, Vitamin D, Calprotectin), quick tests (ColonView FIT, Celiac, H. pylori UFT300, Lactose Intolerance), and the Acetium® consumer medical device line (lozenges for smoking cessation and capsules for stomach protection) containing L-cysteine. Additionally, Biohit offers a comprehensive range of monoclonal antibodies for research applications in cellular pathology, neurobiology, and oncology.

Differentiator

Problem solved

Functional benefit

Brands

• GastroPanel®: Diagnostic panel for assessing gastric mucosal status, atrophic gastritis, and Helicobacter pylori infection
• Acetium®
• ColonView®
• GastroSoft™
• GP Reader NT
• BIOHIT Active B12 (HoloTC)
• BIOHIT Total 25OH Vitamin D
• BIOHIT Calprotectin
• Celiac Quick Test
• Helicobacter pylori UFT300
• Lactose Intolerance Quick Test

Products and services

• GastroPanel® Non-invasive diagnostic concept for assessing stomach health using a panel of serum biomarkers (pepsinogen I, pepsinogen II, gastrin-17, and H. pylori antibodies) to detect atrophic gastritis and assess gastric cancer risk. Available as GastroPanel quick test NT, GastroPanel Unified ELISA, and GastroSoft software.
• GP Reader NT
• GastroSoft™
• BIOHIT Active B12 (HoloTC)
• BIOHIT Total 25OH Vitamin D
• BIOHIT Calprotectin
• BIOHIT ColonView® quick test (FIT)
• BIOHIT Celiac quick test
• BIOHIT Helicobacter pylori UFT300
• Helicobacter pylori quick test
• Lactose Intolerance quick test
• Acetium® lozenge
• Acetium® capsule
• BIOHIT FAEX® Sample System
• BIOHIT Monoclonal Antibodies portfolio

Quantifiable outcome

• GastroPanel achieves ~80% sensitivity and ~90% specificity for atrophic gastritis detection
• +2 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Biohit HealthCare Ltd (UK)coreChannel Partner/ Reseller/ DistributorUK subsidiary serving as regional distribution hub and customer service center for Biohit products in the United Kingdom market. Located in Ellesmere Port, Cheshire.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• DiaSorin: Italian-headquartered IVD company with a broad specialty diagnostics menu including gastric and infectious disease assays on automated immunoassay platforms. Highly comparable as a public specialty diagnostics manufacturer selling biomarker kits and laboratory instruments globally.
• Meridian Bioscience: US-based diagnostics company with strong gastroenterology focus (H. pylori, C. difficile, fecal tests) sold into clinical labs and physician offices. Comparable in product category (GI diagnostics) and channel strategy (distributor-driven specialty diagnostics).
• EKF Diagnostics: UK-based point-of-care and specialty IVD company with products in H. pylori, gastrointestinal, and clinical chemistry testing. Comparable as a small/mid-cap European diagnostics firm offering biomarker kits and rapid tests to similar healthcare professional and laboratory customers.
• ALPCO Diagnostics: US-based specialty IVD company with a strong focus on gastrointestinal disease biomarkers (gastrin, pepsinogen, calprotectin, H. pylori). Directly comparable as a niche diagnostics player addressing the same gastroenterology biomarker indications as Biohit's GastroPanel.

Broad incumbents

• Bio-Rad Laboratories: Large US-headquartered life science and clinical diagnostics company offering ELISA kits, clinical chemistry platforms, and a monoclonal antibody catalog. Comparable as a broad-line IVD incumbent that competes in Biohit's biomarker testing and research reagent segments.
• Roche Diagnostics: Global IVD leader with cobas automated immunoassay platforms that run broad clinical chemistry and infectious disease panels, including gastric-related biomarkers. Comparable as a broad incumbent competitor whose installed base and menu breadth pose a competitive threat to Biohit's hospital and lab customers.
• Abbott Diagnostics: Global IVD leader offering Architect and Alinity immunoassay systems covering gastrointestinal, infectious disease, and clinical chemistry tests. Comparable as a broad-line incumbent whose scale and instrument menus compete with Biohit in hospital and reference lab tenders.
• Thermo Fisher Scientific (Diagnostics): Global life sciences tools and diagnostics company offering ELISA kits, clinical chemistry analyzers, and a research antibody catalog (including Thermo Scientific and Invitrogen brands). Comparable as a broad incumbent competitor in IVD kits and the monoclonal antibody supply business.
• Otsuka Holdings (Diagnostics): Diversified Japanese healthcare group with diagnostic operations including H. pylori testing. Comparable as a broad incumbent with overlap in Biohit's core gastric disease diagnostic space, particularly across Asian markets.

Emerging players

• Exalenz Bioscience: Israel-based company specializing in H. pylori diagnosis via 13C-urea breath test, addressing the same gastric disease detection market as Biohit. Comparable as a focused emerging player in the gastroenterology diagnostic niche.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/biohit
• Facebookfacebook.com/biohitoyj
• LinkedInlinkedin.com/company/biohit-oyj
• Instagraminstagram.com/biohit_oyj

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biohit Healthcare